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Background: Generic drugs (GDs) offer a way to reduce health spending without sacrificing quality. Despite this,
there are doubts as to their acceptance by the population. This work aims to assess perceptions of GDs among the
Brazilian population.
Methods: We conducted a national household survey face-to-face between April and May 2013, with 5000 individuals
aged over 15 years. The questions explored socioeconomic and demographic characteristics, the use of GDs, and
perceptions about GDs as compared to brand drugs (BDs). The chi-square test was used to examine the associations
between the perceptions and the characteristics of the population.
Results: Of the 5000 participants, 51.3% were women, 40.2% were white, 48.6% were between 15 and 34 years of age,
and 52.3% had income of less than two minimum wages (US$627.78). In terms of the use of GDs, 44.6% of the
participants were taking or had taken GDs in the past three months, with the highest figures among the elderly (61.1%)
and female (49.2%) populations. Regarding perceptions, 30.4% of the respondents considered GDs less effective than
BDs; provided the same price, 59% would prefer BD, and 45.8% agreed that physicians prefer to prescribe GDs. The
most negative perceptions about GDs were observed among lower income, elderly and nonwhite populations.
Conclusion: The findings provide a better understanding of Brazilians’ perceptions regarding GDs. This should be
considered when formulating healthcare policies aiming at improving access to effective and quality drugs, and
reduction of health costs.
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According to a survey of family budgets conducted in
2008-2009 by the Brazilian Institute for Geography and
Statistics (IBGE), medicines account for around 48.6%
of the total amount spent on healthcare by Brazilian
families. Among low-income families, this proportion
is as high as 74.2% [1]. In this context, generic drugs
(GDs) offer a good alternative for reducing out-of-pocket
spending by families, without sacrificing product safety
or quality.
GDs were approved by the National Drug Policy, in
October 1998, as a means of promoting rational use of
medicines [2]. The measure was legally consolidated
some months later, in February, 1999 [3]. While ensur-
ing safety and quality, the GD policy aimed to provide* Correspondence: epnardi@unifesp.br
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unless otherwise stated.drugs at lower prices [4]. Since then, the Market share
of GDs in Brazil has grown steadily each year, and by
November 2013, 3,591 generic drugs were registered
with the Brazilian National Health Surveillance Agency
(ANVISA) with 436 different active substances [4].
Nevertheless, generic drugs still have a small market
share in Brazil (27.21% of total volume), particularly
when compared with countries like Germany and the
United Kingdom, which have market shares in 2011 of
76% and 75%, respectively [5,6].
Despite the lower price and the required proof of bio-
equivalence, the replacement and acceptance of generic
drugs still raises questions. In 2001, a study by ANVISA
showed that although 80% of respondents believed that
GDs had the same effect as non-generic drugs, only 48%
asked to replace brand drugs (BDs) for GDs [7]. A more
recent study conducted in southern Brazil found that
33.8% of the 374 respondents either did not know abouthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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United States, which has had regulation of GDs since
1984 (HatchWaxman Act - US Public Law 98-417),
shows concerns about the acceptance of GDs and their
perceptions in the market [9]. Two works published by
William Shank reported that despite a positive attitude
to generics, only about a third of the 1,047 interviewees
preferred GDs, and almost half of the 506 physicians sur-
veyed showed concerns about quality [10,11]. In addition,
the existence of different types of drugs could cause con-
fusion among general population and influence the per-
ception regarding GDs, especially when it is considered
that there are some differences in appearance (e.g. shape,
color and size) between a BD and its GD.
Given the importance of generic drugs on the Brazilian
market with limited financial resources for healthcare,
this work aims to evaluate perceptions of the value and
potential limitations with generic medication among the
Brazilian population.
Methods
This study was part of Brazilian Copcord Study (BRAZCO),
a cross-sectional population based study conducted be-
tween April and May 2013. We surveyed 5,000 participants
over the age of 15 from sixteen capitals of five regions of
Brazil: North (Belém, Manaus), Northeast (Fortaleza, João
Pessoa, Maceió, Natal, Recife and Salvador), Southeast
(Belo Horizonte, Rio de Janeiro and São Paulo), South
(Curitiba, Florianópolis and Porto Alegre), and Midwest
(Brasília and Goiânia).
The sample was comprised of representative quotas of
the Brazilian population, proportional to the population
densities of the capitals in each region of the country,
based on the Census conducted in 2010 by the IBGE. The
quotas of gender and age in each capital were based on
the Census, and participants of all socioeconomic statuses,
educational levels and occupations were included.
The selection of households was random, with system-
atic selection of streets and subjects by randomly drawing
the census tract with quota control for the seasonality fac-
tor. Taking the list of households, one household was eval-
uated per street, up to a total of ten households in the
sector. If an entire sector was covered but not enough
households were found to complete the required number,
the process was re-started in the sector, beginning in the
first street, five houses after the house of the first inter-
view. In each household, up to three visits were made, on
different days and times. In cases where the interview
couldn’t be made after these three attempts, the house-
hold was replaced by another in the same Census sector.
If the resident of the selected household could not be
interviewed, that household was replaced by another in
the same Census Sector, seeking to ensure a respondent
with the same gender and age group.A success rate of 70% was established, so 42.9% more
households than planned were randomly selected to en-
sure substitution. Ineligible households, such as collective
households (vacant households, hotels, lodges, nursing
homes, etc.), agricultural, educational and healthcare
establishments, and buildings under construction, were
replaced by another in the same Census sector. The max-
imum sampling error was ±1.39% for the country as a
whole, with a 95% confidence level.
Residents who did not speak Portuguese, and people with
cognitive disability being incapable of reliably and consist-
ently answering the questionnaire were excluded. Because
the minor proportion of people living in rural areas (15.6%)
and the difficulty of access this scattered population, only
households in urban area were considered [12].
The survey instrument was a household questionnaire
conducted face-to-face by a specialized team, consisting
of open and closed-ended questions about socioeco-
nomic and demographics aspects, and the use of GDs in
the past three months. Race was declared by the respon-
dents themselves (black, mixed race, Asian, or Indigenous)
and then classified as white or nonwhite. Family income
was expressed as multiples of minimum wages, where the
values of the Brazilian minimum wage, originally in Reais
(Brazilian currency), were converted to United States
dollars (US$) according to the exchange rate of 2013
using data from Institute of Applied Economic Research
(IPEA – Instituto de Pesquisa Econômica Aplicada) [13].
To evaluate the perceptions on GDs as compared to
BDs, four multiple choice questions (agree, disagree or
don’t know) were presented to the participants, concern-
ing effectiveness, use, individual preference and physi-
cians’ preferences. To reduce bias among the respondents
regarding their opinions about GDs, two sentences con-
cerning the BDs were included: “Brand drugs cause more
side effects (adverse reactions) than generic drugs” and
“Brand drugs take more time to the effect when compared
to generic drugs”. The statements tried to avoid systemat-
ically favor or disfavor BDs or GDs.
The questionnaires were reviewed by an independent
supervisor and submitted to a process of evaluation of
consistency, where 50% of the questionnaires were
double checked through phone calls.
Descriptive statistics were used to examine the charac-
teristics of the participants. The Chi-square test was
used to examine the associations between the perception
and the characteristics of the population. Statistical ana-
lyses were performed using the Minitab software, version
16, and statistical significance was assumed for p-values
less than or equal to 0.05.
All participants were informed about the study and
signed a consent form. The study protocol was reviewed
and approved by the Research Ethics Committee of the
Federal University of São Paulo.
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Table 1 presents the main demographics and socioeco-
nomic characteristics of the surveyed population, and the
number of participants who were taking or had taken
GDs in the past three months.
A total of 5000 participants from 16 capitals of five
Brazilian geographic regions were surveyed: 415 partici-
pants from the North (8.3%), 1390 from the Northeast
(27.8%), 2105 from Southeast (42.1%), 720 from SouthTable 1 Demographics and socioeconomic characteristics of t
of generic drugs
Bra
N
Total 190
Gender
Male 93
Female 97
Age (years)
15 to 34 67
35 to 64 63
≥65 14
Region
North 15
Northeast 53
Midwest 14
Southeast 80
South 27
Race
White 91
Nonwhite 99
Marital statusb
Single 89
Married 56
Living common law _
Widowed 8 0
Divorced/Separated 7 8
Did not answer -
Family income (minimum wages)b
Less than 2 (US$ 627.78) 75
From 2 – 10 24
More than 10 (US$3,138.89) 2 6
Did not answer -
Was taking or had taken GD in the past three months
Yes -
Note: aSource: Instituto Brasileiro de Geografia e Estatística – IBGE, Censo 2010: http://ww
shtm.
Note: b ≥ 10 years (n = 161 981 299).(14.4%), and 370 from Midwest (7.4%). Of the participants,
n = 2567 (51.3%) were women, and 40.2% (n = 2009)
described themselves as white. The participants were
predominantly between 15 and 34 years old (48.6%) and
52.3% had a family income of up to two minimum wages,
or US$627.78.
Of all the participants, 44.6% were taking or had taken
GDs in the past three months. Table 2 describes the use
of generic drugs, according to the characteristics ofhe Brazilian population, study sample (n = 5000) and use
zilian populationa Participants
% N %
755 799 - 5000 -
406 990 49.0 2433 48.7
348 809 51.0 2567 51.3
084 990 46.3 2430 48.6
657 038 44.0 2097 41.9
081 477 9.7 473 9.5
864 454 8.3 415 8.3
081 950 27.8 1390 27.8
058 094 7.4 370 7.4
364 410 42.1 2105 42.1
386 891 14.4 720 14.4
051 646 47.7 2009 40.2
697 545 52.3 2991 59.8
653 403 55.3 2053 41.1
435 253 34.8 1632 32.6
810 16.2
63 404 5.0 240 4.8
29 238 4.8 233 4.7
- 32 0.6
073 409 46.3 2615 52.3
140 811 14.9 2079 41.6
86 709 1.7 218 4.4
- 88 1.7
- 2230 44.6
w.ibge.gov.br/home/estatistica/populacao/censo2010/default_resultados_universo.
Table 2 Proportion of peoples who were taking or had
taken GD in the past three months
Was taking or had taken GD
in the past three months
N (%) p-value
All 2230 (44.6)
Gender
Male 968 (39.8) <0.001
Female 1262 (49.2)
Age
15 - 34 years 935 (38.5) <0.001
35 - 64 years 1006 (48.0)
≥65 years 289 (61.1)
Race
White 906 (45.1) 0.562
Nonwhite 1324 (44.3)
Family income (minimum wages)a
Less than 2 (US$ 627.78) 1159 (44.3) 0.380
2 a 10 938 (45.1)
More than 10 (US$3,138.89) 107 (49.1)
Did not answer 26 (29.5)
Note: aOnly included those who reported family income during the interview.
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months was among females (49.2%, p < 0.001) and in the
population over the age of 65 (61.1%, p < 0.001).
Tables 3 and 4 show the perceived value attributes
expressed by all the participants, of GDs when compared
to BDs, stratified by some demographics and economic
characteristics of the sample.
The majority of participants (58.8%) disagreed with
the statement that “GDs are less effective than BDs”.
Older and nonwhite participants expressed less disagree-
ment than younger participants (p < 0.001) and white (p
< 0.001) participants, respectively. Participants who was
taking or had taken GD in the past three months also
disagreed more than those who had not (p < 0.001).
Lower family income was associated with less disagree-
ment with this statement than higher income (p < 0.001).
However, approximately one third of all participants
(30.3%) agreed that GDs are less effective than BDs. The
level of agreement ranged from 24.3% in the high income
group to 35.2% in the group of people aged over 54.
The majority of participants (56.0%) disagreed with
the statement that “BDs cause more side effects (adverse
effects) than GDs”. Nonwhite participants also expressed
less disagreement with this statement (p < 0.001) than
white participants. Again, higher income was correlated
with more disagreement (p < 0.001). On the other hand,
28.1% of the entire sample agreed with this statement
ranging from an agreement by 15.1% of the highestincome group to an agreement of 32.6% of the nonwhite
population.
Regarding the statement “BDs take more time to
the effect than GDs”, 73.4% of the participants did not
agree with it. This trend was observed in all subgroups,
however a statistically significant increase in the level of
disagreement was observed among higher family income
groups (p < 0,001). The overall agreement with this state-
ment was 12.6%.
When asked about their perceptions of the statement
“GDs are more suitable or appropriate than BDs for mild
or less serious diseases”, a slightly higher percentage of
participants (46.9%) disagreed with this statement. This
disagreement was higher among white participants
(53.5%, p < 0.001) and in the higher family income
groups (p < 0.011). The overall agreement with this state-
ment was 41% with the highest level of agreement in the
nonwhite population (45.7%) and the lowest level of
agreement in the white population (34%).
A slightly higher proportion of participants (45.8%)
agreed with the statement “Physicians prefer to prescribe
GDs”. Females (49.0%) and the lowest family income
group (50.4%) tended to agree more with it (p < 0.001).
A disagreement was indicated by 41.8% of the total sam-
ple with the highest level of disagreement in the highest
income group (55.1%) and the lowest disagreement
among the lowest income participants (37.5%).
Finally, the majority of participants (59.2%) agreed
with the statement “If there were no price difference
(GDs are cheaper), I would always prefer to take a BD”.
Comparing all the subgroups tested, only the nonwhite
group expressed a greater and relevant disagreement
(31.5%) with this statement when compared to the white
group (36%; p < 0.001). Other observed statistically sig-
nificant differences between subgroups were very small
and therefore not important.
Discussion
This work was the first nationwide survey evaluating the
use and perception of GDs among the Brazilian popula-
tion. Given that cost and reliance on drugs have been
suggested in previous studies as key factors influencing
adherence to medication, it is important to reduce indi-
vidual healthcare costs in order to increase patients’
adherence to drug therapy [14].
Rural area residents were excluded from the sample, be-
cause of its minor proportion comparing to total of Brazilian
population (15.6%) and the difficulty of access this scat-
tered population [12]. It is worth emphasizing that, on
the last Census, the quotas of gender and age in rural
areas are similar to the urban population: (i) Urban –
Male 48.3% and Female 51.7%; Rural – Male: 52.6% and
Female: 47.4%; (ii) Urban - 15 to 34 years: 46.2%, 35
to 64 years: 44.2%, ≥65 years: 9.6%, and Rural - 15 to
Table 3 Perception of value attributes of generic drugs according to gender, age and use of generic drugs
All (n = 5000) Gender Age (years) Was taking or had taken GD
in the past three months
N(%) Male Female 15-34 35-54 >54 Yes No
Generic drugs are less effective
(less powerful) than brand name drugs
I agree 1520 (30.4) 741 (30.5) 779 (30.3) 660 (27.2) 521 (32.4) 339 (35.2) 642 (28,8) 878 (31,7)
I disagree 2942 (58.8) 1393 (57.3) 1549 (60.3) 1526 (62.8) 918 (57.1) 498 (51.7) 1404 (63,0) 1538 (55,5)
I don’t know/
Did not answer
538 (10.8) 299 (12.3) 239 (9.3) 244 (10.0) 168 (10.5) 126 (13.1) 184 (8,3) 354 (12,8)
p-valuea 0.375 <0.001 <0.001
Brand drugs cause more side effects
(adverse reactions) than generic drugs.
I agree 1403 (28.1) 694 (28.5) 709 (27.6) 670 (27.6) 463 (28.8) 270 (28.0) 619 (27,8) 784 (28,3)
I disagree 2798 (56.0) 1328 (54.6) 1470 (57.3) 1396 (57.4) 914 (56.9) 488 (50.7) 1283 (57,5) 1515 (54,7)
I don’t know/
Did not answer
799 (16.0) 411 (16.9) 388 (15.1) 364 (15.0) 230 (14.3) 205 (21.3) 328 (14,7) 471 (17,0)
p-valuea 0.220 0.275 0.287
Brand drugs take more time to the
effect when compared to generic drugs
I agree 632 (12.6) 325 (13.4) 307 (12.0) 308 (12.7) 192 (12.0) 132 (13.7) 261 (11,7) 371 (13,4)
I disagree 3672 (73.4) 1748 (71.8) 1924 (74.9) 1789 (73.6) 1233 (76.7) 650 (67.5) 1698 (76,1) 1974 (71,3)
I don’t know/
Did not answer
696 (13.9) 360 (14.8) 336 (13.1) 333 (13.7) 182 (11.3) 181 (18.8) 271 (12,2) 425 (15,3)
p-valuea 0.076 0.097 0.021
Generic drugs are more suitable or
appropriate than brand name drugs
for mild, banal or less serious diseases.
I agree 2049 (41.0) 1024 (42.1) 1025 (39.9) 974 (40.1) 670 (41.7) 405 (42.1) 904 (40,5) 1145 (41,3)
I disagree 2344 (46.9) 1106 (45.5) 1238 (48.2) 1181 (48.6) 772 (48.0) 391 (40.6) 1104 (49,5) 1240 (44,8)
I don’t know/
Did not answer
607 (12.1) 303 (12.5) 304 (11.8) 275 (11.3) 165 (10.3) 167 (17.3) 222 (10,0) 385 (13,9)
p-valuea 0.065 0.023 0.048
Physicians prefer to prescribe
generic drugs.
I agree 2289 (45.8) 1032 (42.4) 1257 (49.0) 1160 (47.7) 706 (43.9) 423 (43.9) 1051 (47,1) 1238 (44,7)
I disagree 2090 (41.8) 1035 (42.6) 1055 (41.1) 978 (40.3) 708 (44.1) 404 (42.0) 971 (43,5) 1119 (40,4)
I don’t know/
Did not answer
621 (12.4) 366 (15.0) 255 (9.9) 292 (12.0) 193 (12.0) 136 (14.1) 208 (9,3) 413 (14,9)
p-valuea 0.003 0.032 0.718
If there was not a price difference
(generics are cheaper), I would always
prefer taking a brand name drug.
I agree 2962 (59.2) 1438 (59.1) 1524 (59.4) 1403 (57.7) 994 (61.8) 565 (58.7) 1363 (61,1) 1599 (57,7)
I disagree 1666 (33.3) 780 (32.1) 886 (34.5) 847 (34.9) 504 (31.4) 315 (32.7) 743 (33,3) 923 (33,3)
I don’t know/
Did not answer
372 (7.4) 215 (8.8) 157 (6.1) 180 (7.4) 109 (6.8) 83 (8.6) 124 (5,6) 248 (9,0)
p-valuea 0.258 0.044 0.352
Note: aOnly included those who answered the statements.
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Table 4 Perception of value attributes of generic drugs according to race and family income
All (n = 5000) Race Family Income (minimum wages)a
N(%) White Nonwhite 1 - 2 2 - 10 >10 Did not answered
Generic drugs are less effective
(less powerful) than brand name
drugs
I agree 1520 (30.4) 545 (27.1) 975 (32.6) 848 (32.4) 598 (28.8) 53 (24.3) 21 (23.9)
I disagree 2942 (58.8) 1258 (62.6) 1684 (56.3) 1456 (55.7) 1291 (62.1) 140 (64.2) 55 (62.5)
I don’t know/
Did not answer
538 (10.8) 206 (10.3) 332 (11.1) 311 (11.9) 190 (9.1) 25 (11.5) 12 (13.6)
p-valueb <0.001 <0.001
Brand drugs cause more side effects
(adverse reactions) than generic drugs.
I agree 1403 (28.1) 444 (22.1) 959 (32.1) 861 (32.9) 492 (23.7) 33 (15.1) 17 (19.3)
I disagree 2798 (56.0) 1243 (61.9) 1555 (52.0) 1323 (50.6) 1272 (61.2) 146 (67.0) 57 (64.8)
I don’t know/
Did not answer
799 (16.0) 322 (16.0) 477 (15.9) 431 (16.5) 315 (15.2) 39 (17.9) 14 (15.9)
p-valueb <0.001 <0.001
Brand drugs take more time to the
effect when compared to generic drugs
I agree 632 (12.6) 209 (10.4) 423(14.1) 382 (14.6) 221 (10.6) 20 (9.2) 9 (10.2)
I disagree 3672 (73.4) 1514 (75.4) 2158 (72.1) 1856 (71.0) 1589 (76.4) 173 (79.3) 54 (61.4)
I don’t know/
Did not answer
696 (13.9) 286 (14.2) 410 (13.7) 377 (14.4) 269 (13.0) 25 (11.5) 25 (28.4)
p-valueb <0.001 <0.001
Generic drugs are more suitable or
appropriate than brand name drugs
for mild, banal or less serious diseases.
I agree 2049 (41.0) 683 (34.0) 1366 (45.7) 1164 (44.5) 789 (38.0) 80 (36.7) 16 (18.2)
I disagree 2344 (46.9) 1074 (53.5) 1270 (42.5) 1120 (42.8) 1054 (50.7) 112 (51.4) 58 (65.9)
I don’t know/
Did not answer
607 (12.1) 252 (12.5) 355 (11.9) 331 (12.7) 236 (11.3) 26 (11.9) 14 (15.9)
p-valueb <0.001 <0.001
Physicians prefer to prescribe
generic drugs.
I agree 2289 (45.8) 851 (42.4) 1438 (48.1) 1317 (50.4) 896 (43.1) 62 (28.4) 14 (15.9)
I disagree 2090 (41.8) 886 (44.1) 1204 (40.3) 981 (37.5) 959 (46.1) 120 (55.1) 30 (34.1)
I don’t know/
Did not answer
621 (12.4) 272 (13.5) 349 (11.7) 317 (12.1) 224 (10.8) 36 (16.5) 44 (50.0)
p-valueb <0.001 <0.001
If there was not a price difference
(generics are cheaper), I would always
prefer taking a brand name drug.
I agree 2962 (59.2) 1114 (55.5) 1848 (61.8) 1609 (61.5) 1201 (57.8) 127 (58.3) 25 (28.4)
I disagree 1666 (33.3) 723 (36.0) 943 (31.5) 827 (31.6) 731 (35.2) 73 (33.5) 35 (39.8)
I don’t know/
Did not answer
372 (7.4) 172 (8.6) 200 (6.7) 179 (6.9) 147 (7.1) 18 (8.3) 28 (31.8)
p-valueb <0.001 0.028
Note: aOnly included those who reported family income during the interview; bOnly included those who answered the statements.
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10.5% [12].
In this study, GDs have or had been used by 44.6% of
the population within the past three months. This figure
is higher than the frequency found in 2006/2007 in an
area covered by a family health unit in a city in southern
Brazil (9.9%). It is also higher than that found in another
southern Brazilian city in 2002 (3.6%) [8,15]. These dif-
ferences can be explained by the three month period
used in the present study, as compared with the 7 and
15 days, respectively, used in the previous studies. More-
over, it can be explained by the ease of access to these
drugs, since the market share of GDs has increased al-
most three-fold in Brazilian healthcare centers through-
out the past five years [5].
Higher use of GDs was observed in the female and
elderly populations, which can be explained by the
higher use of medicines in general, by these two groups
[16,17]. The higher use of GDs among the elderly popu-
lation may also be related to their lower spending power,
which may cause a preference for cheaper products like
GDs. In August 2013, GDs were, on average, 56.63%
cheaper than their respective brand name drugs (BDs) in
Brazil [18].
Regarding the participants’ perceptions of the attributes
of GDs, it was observed that almost a third (30.4%)
believed GDs were less effective than BDs, and the most
negative opinions were observed in the lower income,
elderly and nonwhite populations. These results are con-
sistent with previous studies, which found unfavorable
opinions on the effectiveness, safety, tolerability and
acceptance of GDs associated with low income, nonwhite
race and advanced age of the respondents [11,19-22]. This
raises a concern as to the acceptance of GDs and the
adherence to drug therapy in these groups.
Additionally, participants who was taking or had taken
GD in the past three months disagreed more with the
statement that GDs were less effective than BDs. It is
possible to assume that experience with GDs could possibly
influence attitudes in a positive way.
In 2001 the National Health Surveillance Agency
(ANVISA) surveyed 2,220 customers in 236 different cit-
ies, and observed that 80% of the participants were
confident that GDs had the same effect as BDs [23]. A
study conducted in the state of Rio Grande do Sul in
2002 found that 70% of the 3,182 participants believed
GDs had similar quality compared to BDs, and a study
conducted in Paraná in 2011 showed that 64.3% of the
374 participants were of the same opinion [8,15]. In this
study, the majority of 58.8% of the 5,000 participants
disagreed that GDs are less effective than BDs. This may
represent a decline in the credibility of GD over the
years. On the other hand, there were several differences
between the surveys which may explain the variation:this study covered a greater population and more
regions than previous studies and used a different survey
approach concerning questions and methodology.
Although most of participants had a positive perception
regarding the effectiveness of GDs, 59% said that if there
were no price difference, they would prefer BDs. This
finding reinforces the idea that price has a strong influ-
ence on the decision to purchase a GD, which was ob-
served in a study conducted in the North of Brazil that
evaluated the social representations of GDs by consumers
and demonstrated price as a fundamental element in
building product value and guiding market choice [24].
The findings indicate an underuse of GDs, with 41% of
the participants agreeing with the statement “Generic
drugs are more suitable or appropriate than brand name
drugs for mild, banal or less serious diseases”. This result
is in line with previous findings that participants would
be more willing to use generics for less serious diseases,
and it suggests that they may be more reluctant to use
them for more serious diseases [21,25,26].
Another important finding is that a significant portion
of the population agreed that BDs cause more side
effects than GDs (28.1%). This proportion increased to
almost a third when we evaluated only nonwhite and
low-income populations. One possible explanation for
this result is that some participants may see generics as
products with reduced effectiveness, compared with
brand name drugs, because they consider GDs to be less
effective. Thus, BDs are perceived as stronger medica-
tions, and would cause more side effects than generics.
The work, conducted by Sewell (2012), also indicated a
perception regarding GDs as a weaker product. How-
ever, Sewell observed that GDs were perceived as having
to be stronger to produce the same effect as BDs, lead-
ing to more side effects, contrary to what we found
in the present study [26]. However, the expectation
for more adverse events with BDs may be due to the
perceived higher strength. More studies, and a better
understanding regarding the population’s perceptions,
are needed to confirm this finding and the underlying
reasons.
Given the importance of physicians’ views as opinion
leaders in the use of GDs, we also evaluated the popula-
tion’s perceptions regarding the preference of these pro-
fessionals. Less than half of the participants agreed with
the statement that physicians prefer to prescribe generic
drugs (45.8%). Moreover, it was observed that the low-
income participants were more of the opinion that phy-
sicians prefer to prescribe GDs than the higher income
population. We consider this difference by income to
be positive, since this result indicates that physicians
take socioeconomic criteria into account when making
prescriptions. Another explanation is the greater use of
the public health system by people with low incomes.
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(PNAD) conducted in 2008 by the IBGE, and a study by
Zilda Pereira da Silva (2006), the population belonging
to the first quintile (poorest 20%) is the main user of the
public health system in Brazil [27,28]. Physicians from
the public health system are obliged to prescribe drugs
by their Brazilian Common Denomination (Denomina-
ção Comum Brasileira - DCB) or, in its absence, by the
International Nonproprietary Name (INN) [29]. In these
cases, users of public health system received more pre-
scriptions for GDs than users of private health systems.
Evaluating perceptions on the attributes of generic
drugs by gender, we found no statistically significant
differences between the responses of women and men,
except that women agreed more with the statement that
physicians prefer to prescribe GDs. This finding differs
from the study conducted by Shank (2009), which
observed that women were more likely than men to
report that generics offer better value than brand name
drugs [11]. A potential explanation for the perceived
higher prescribing of GDs among the women could be
that a higher percentage of women tends to be in the
lower income class and thus, more women may depend
on the public system [30]. This effect would be even
more pronounced for the differences between races [31].
The present work investigated the population’s percep-
tion regarding GDs, but did not investigate the reasons
for the perceptions. It is necessary to explore the under-
lying reasons, for instance, if the negative perception that
part of population has regarding GD is caused by lack of
knowledge between the two types of drugs. Moreover, it is
necessary to investigate whether the regulation and health
surveillance concerning GDs in Brazil are appropriate
to ensure effectiveness and interchangeable products with
assured quality.
It is also necessary to educate the general public with re-
gard to correct and conscious use of the different types of
drugs. As suggested by a study conducted by Joan-Antoni
Vallès (2002) in Spain, verbal information and the distri-
bution of explanatory material about GDs for patients will
increase their use [32]. However, further studies are
needed to confirm the importance of patient education in
the choice of drugs in Brazil.Conclusions
Our findings demonstrate that although the majority of
participants have a positive attitude towards GDs, there is
a considerable percentage who expressed concerns about
these drugs, particularly the older, low income and non-
white populations. That more negative attitudes towards
GDs are observed with elderly and low income popula-
tions is in contrast to their greater need for affordable
products. A perceived inferiority of generics and highercost of branded drugs may lead to lower adherence to
drug therapy among these population groups.
A better understanding of individual perceptions re-
garding GDs can stimulate actions that will improve the
effective use of generic drugs by the Brazilian population
and guide the formulation of appropriate health policies
aimed at increasing access to effective, safe and afford-
able drugs.
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